Literature DB >> 17453720

Anti-ribonucleoprotein antibodies mediate enhanced lung injury following mesenteric ischemia/reperfusion in Rag-1(-/-) mice.

Michael P Keith1, Chantal Moratz, Ryan Egan, Athina Zacharia, Eric L Greidinger, Robert W Hoffman, George C Tsokos.   

Abstract

Natural Abs and autoantibodies bind antigens displayed by ischemia-conditioned tissues, followed by complement activation and enhanced tissue injury during reperfusion. Anti-ribonucleoprotein (RNP) Ab is associated with lung disease in patients with autoimmune disease but it is not known whether these abs contribute to lung injury. Mesenteric I/R in mice leads to local and remote lung injury. Accordingly, we used this model to investigate whether anti-RNP Abs would reconstitute I/R damage with prominent lung damage in injury-resistant Rag1(-/-) animals. Rag1(-/-) mice injected with anti-RNP Ab containing serum and subjected to mesenteric I/R suffered greater intestinal injury than control-treated and sham-operated animals. The magnitude of the reconstituted damage was anti-RNP Ab titer-dependent. Anti-RNP Ab-treated animals demonstrated a dose-dependent increase in lung histologic injury scores compared to control and sham animals. Anti-RNP mediated injury was shown to be complement dependent. These experiments reveal a novel mechanism whereby anti-RNP Abs contributes to the development of pulmonary pathology in patients with autoimmune diseases following exposure of remote organs to I/R injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453720     DOI: 10.1080/08916930701262986

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  8 in total

1.  CR2+ marginal zone B cell production of pathogenic natural antibodies is C3 independent.

Authors:  Keith M Woods; Michael R Pope; Sara M Hoffman; Sherry D Fleming
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

2.  Epitope mapping of the U1 small nuclear ribonucleoprotein particle in patients with systemic lupus erythematosus and mixed connective tissue disease.

Authors:  J A Somarelli; A Mesa; R Rodriguez; R Avellan; L Martinez; Y J Zang; E L Greidinger; R J Herrera
Journal:  Lupus       Date:  2011-03       Impact factor: 2.911

Review 3.  Pediatric Mixed Connective Tissue Disease.

Authors:  Roberta A Berard; Ronald M Laxer
Journal:  Curr Rheumatol Rep       Date:  2016-05       Impact factor: 4.592

4.  TLR2 modulates antibodies required for intestinal ischemia/reperfusion-induced damage and inflammation.

Authors:  Michael R Pope; Sherry D Fleming
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

Review 5.  The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases.

Authors:  Nicole H Kattah; Michael G Kattah; Paul J Utz
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

6.  Domain V peptides inhibit beta2-glycoprotein I-mediated mesenteric ischemia/reperfusion-induced tissue damage and inflammation.

Authors:  Sherry D Fleming; Michael R Pope; Sara M Hoffman; Tiffany Moses; Urska Bukovnik; John M Tomich; Lynn M Wagner; Keith M Woods
Journal:  J Immunol       Date:  2010-10-18       Impact factor: 5.422

7.  Tissue targeting of anti-RNP autoimmunity: effects of T cells and myeloid dendritic cells in a murine model.

Authors:  Eric L Greidinger; Yunjuan Zang; Irina Fernandez; Mariana Berho; Mehdi Nassiri; Laisel Martinez; Robert W Hoffman
Journal:  Arthritis Rheum       Date:  2009-02

8.  TLR9 is dispensable for intestinal ischemia/reperfusion-induced tissue damage.

Authors:  Emily Archer Slone; Michael R Pope; Mary Roth; Ruth Welti; Sherry D Fleming
Journal:  Am J Clin Exp Immunol       Date:  2012
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.